Tenax plummets on phase 3 failure of pulmonary hypertension drug

Tenax's stock price has plummeted due to the failure of its clinical trial phase 3 for a pulmonary arterial hypertension treatment.

AI CATALYST SCORE45 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

Diagnosed At	Ticker	AI Score	Tier
2026-08-30 19:04:08	TENX	50	Row	View Report →
2026-08-29 12:30:37	TENX	65	Mid	View Report →
2026-08-25 11:48:51	TENX	75	Mid	View Report →

TENX Analysis History (Last 30 Days)